Art. -Nr.: HY-100111

GLX351322

55 Cited Publications

Kundenbewertung

Based on 55 publication(s) in Google Scholar

GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC₅₀ of 5 μM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.48%
CAS. Nr.: 835598-94-2
Formel: C₂₁H₂₅N₃O₅S
Molecular Weight:431.51

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 2 years , -20°C, 1 year

GLX351322 Chemical Structure

CAS. Nr.: 835598-94-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (55)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC₅₀ of 5 μM.

IC₅₀ & Target

NOX4

Alle NADPH Oxidase Isoform-spezifische Produkte anzeigen :

In Vitro

GLX351322 is an inhibitor of NADPH oxidase 4, and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC₅₀ of 5 μM. GLX351322 shows weak activity against NOX2 in hPBMC cells (IC₅₀, 40 μM).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GLX351322 (3.8 mg/kg/day, p.o.) ameliorates HFD-induced hyperglycemia in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 835598-94-2
Appearance Solid
Molecular Weight 431.51
Formel C₂₁H₂₅N₃O₅S
Color White to off-white
SMILES

O=C(OCC)C1=C(SC2=C1CCC2)NC(CN3CCN(CC3)C(C4=CC=CO4)=O)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (55)

All Bio/Physico-chemical AssayIFFlow CytometryCell Proliferation/Viability AssayCell Imaging/StainingWB

Sort by:

Journal Impact Factor

Cell Metab

NAD-dependent redox control enables endothelial quiescence and vascular stabilization during angiogenesis. [Abstract]

2026 Apr 29:S1550-4131(26)00142-7. PMID: 42061402
Cell Host Microbe

Type I interferons induce guanylate-binding proteins and lysosomal defense in hepatocytes to control malaria. [Abstract]

2025 Apr 9;33(4):529-544.e9. PMID: 40168996

GLX351322 purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2025 Apr 9;33(4):529-544.e9. [Abstract]

GLX351322 (10 μM; 6 h) impaired IFN-I-mediated control of P. berghei infection in primary mouse (B6) hepatocyte cultures.
Adv Sci (Weinh)

Magnetically-Induced Suppression of Oxidative Stress Prevents Venous Thrombosis. [Abstract]

2025 Nov 21:e13299. PMID: 41272999

GLX351322 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 21:e13299. [Abstract]

Representative immunofluorescence images of ROS in C166 cells subjected to 0.4 mM H₂O₂ following NOX4 enzyme inhibition by GLX351322 (20 µM; 24 h) .

GLX351322 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 21:e13299. [Abstract]

Flow cytometry quantification of ROS in C166 cells subjected to 0.4 mM H₂O₂ following NOX4 enzyme inhibition by GLX351322 (20 µM; 24 h).

GLX351322 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 21:e13299. [Abstract]

Cell viability of C166 cells subjected to 0.4 mM H₂O₂ with or without GLX351322 (20 µM; 24 h) pretreatment.

GLX351322 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 21:e13299. [Abstract]

GLX351322 (20 µM). Assessment of intracellular ROS levels in C166 cells by fluorescence microscopy (DCFH-DA staining) following H₂O₂ challenge.
Redox Biol

Podocyte SIRPα reduction in diabetic nephropathy aggravates podocyte injury by promoting pyruvate kinase M2 nuclear translocation. [Abstract]

2024 Nov 20:78:103439. PMID: 39586122
Appl Phys Rev

2026 Jan 21.
Alzheimers Dement

2020;16(Suppl. 3):e038198.
MedComm (2020)

Ipriflavone From Aquilaria malaccensis Lam. Exosome-Like Nanoparticles Targets Prolyl Hydroxylase Domain Protein 2 (PHD2) to Enhance Hypoxia-Inducible Factor-α (HIF-α) Hydroxylation Thereby Alleviating Hypoxia-Induced Gastrointestinal Mucosal Ferroptosis. [Abstract]

2026 Apr 9;7(4):e70722. PMID: 41969632
Cell Mol Biol Lett

Extracellular vesicles derived from CD4+ T cells carry DGKK to promote sepsis-induced lung injury by regulating oxidative stress and inflammation. [Abstract]

2023 Mar 23;28(1):24. PMID: 36959535
Int J Biol Macromol

Carboxyl group-modified α-lactalbumin induces TNF-α-mediated apoptosis in leukemia and breast cancer cells through the NOX4/p38 MAPK/PP2A axis. [Abstract]

2021 Sep 30:187:513-527. PMID: 34310992
Acta Pharmacol Sin

TIGAR overexpression alleviates intracerebral hemorrhage injury in mice by suppressing ATF4/NOX4/p22phox-mediated oxidative stress and inflammation. [Abstract]

2026 May 7. PMID: 42098398
Free Radic Biol Med

The autophagy receptor NDP52 recruits the E3 ligase ASB2 to mediate NOX4 degradation, suppressing cardiomyocyte ferroptosis and ameliorating heart failure. [Abstract]

2026 Apr:247:378-392. PMID: 41662915
Free Radic Biol Med

USP38 stabilizes NOX4 and activates CaMKII to enhance ventricular arrhythmias susceptibility in CKD mice. [Abstract]

2025 Sep:237:344-356. PMID: 40482978
Free Radic Biol Med

MAGL inhibition relieves synovial inflammation and pain via regulating NOX4-Nrf2 redox balance in osteoarthritis. [Abstract]

2023 Nov 1:208:13-25. PMID: 37516370
Free Radic Biol Med

Nox4 promotes osteoblast differentiation through TGF-beta signal pathway. [Abstract]

2022 Nov 20;193(Pt 2):595-609. PMID: 36372285
Biomed Pharmacother

Cyanidin-3-glucoside confers neuroprotection in ischemic stroke by targeting NOX4-mediated oxidative stress: A network pharmacology and experimental validation study. [Abstract]

2026 Feb:195:119072. PMID: 41616469
Redox Rep

Norepinephrine promotes oxidative stress in vascular adventitial fibroblasts via PKC/NFκB-mediated NOX2 upregulation. [Abstract]

2025 Dec;30(1):2494314. PMID: 40269356
Cell Death Discov

BRD4 Inhibition alleviates sepsis-associated acute kidney injury via suppression of NOX4-mediated oxidative stress and inflammation. [Abstract]

2026 Apr 21;12(1):266. PMID: 42014688
Neural Regen Res

NOX4 exacerbates Parkinson's disease pathology by promoting neuronal ferroptosis and neuroinflammation. [Abstract]

2025 Jul 1;20(7):2038-2052. PMID: 38993139
Int J Nanomedicine

GLX351322-Loaded Nanoparticles Alleviate Chronic Stress-Induced Depressive Behaviors Through Inhibition of Ferroptosis and Oxidative Stress. [Abstract]

2025 Nov 24:20:14033-14055. PMID: 41321900
Phytother Res

l-Theanine Improves Learning and Memory Through Attenuation of NOX4-Mediated Ferroptosis in Hippocampal Neurons of Sleep-Deprived Mice. [Abstract]

2025 Jul 19. PMID: 40682446
Cell Biol Toxicol

Effects of SIDT2 on the miR-25/NOX4/HuR axis and SIRT3 mRNA stability lead to ROS-mediated TNF-α expression in hydroquinone-treated leukemia cells. [Abstract]

2023 Oct;39(5):2207-2225. PMID: 35302183
Int J Mol Med

Endothelial NOX4‑driven oxidative stress inhibition reverses HtrA1 deficiency‑induced blood‑brain barrier disruption and cognitive impairment. [Abstract]

2026 Jul;58(1):194. PMID: 42169653
Biochem Pharmacol

Furanodienone induces apoptosis via regulating the PRDX1/MAPKs/p53/caspases signaling axis through NOX4-derived mitochondrial ROS in colorectal cancer cells. [Abstract]

2024 Jul 28:116456. PMID: 39079582
Biochem Pharmacol

ONC212 enhances YM155 cytotoxicity by triggering SLC35F2 expression and NOXA-dependent MCL1 degradation in acute myeloid leukemia cells. [Abstract]

2024 Jun:224:116242. PMID: 38679209
Biochem Pharmacol

Hydroquinone-selected chronic myelogenous leukemia cells are sensitive to chloroquine-induced cytotoxicity via MCL1 suppression and glycolysis inhibition. [Abstract]

2023 Dec:218:115934. PMID: 37989415
Biochem Pharmacol

BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells. [Abstract]

2023 Sep:215:115738. PMID: 37562509
Biochem Pharmacol

Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells. [Abstract]

2023 May:211:115494. PMID: 36924905
Biochem Pharmacol

AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells. [Abstract]

2023 Mar:209:115442. PMID: 36720359
Biochem Pharmacol

Docetaxel-triggered SIDT2/NOX4/JNK/HuR signaling axis is associated with TNF-α-mediated apoptosis of cancer cells. [Abstract]

2022 Jan:195:114865. PMID: 34863979
Cells

Naja atra Cardiotoxin 1 Induces the FasL/Fas Death Pathway in Human Leukemia Cells. [Abstract]

2021 Aug 12;10(8):2073. PMID: 34440842
Pharmaceuticals (Basel)

Carboxyl Group-Modified Myoglobin Induces TNF-α-Mediated Apoptosis in Leukemia Cells. [Abstract]

2022 Aug 27;15(9):1066. PMID: 36145287
Int Immunopharmacol

Curcumin modulates oxidative stress via NOX4 to ameliorate endometrial hyperplasia. [Abstract]

2025 Aug 19:164:115392. PMID: 40834530
Int Immunopharmacol

Vaccarin alleviates renal ischemia-reperfusion injury by inhibiting inflammation and ferroptosis. [Abstract]

2025 Apr 24:153:114463. PMID: 40112596
Int Immunopharmacol

NOX4 regulates gastric cancer cell invasion and proliferation by increasing ferroptosis sensitivity through regulating ROS. [Abstract]

2024 May 10:132:112052. PMID: 38593505
Toxicology

NOX4/Keap1/Nrf2/ROS signaling drives ferroptosis in trimethyltin chloride-induced cardiac developmental malformations. [Abstract]

2026 Mar:521:154394. PMID: 41485541
J Cell Mol Med

SIRT3, PP2A and TTP protein stability in the presence of TNF-α on vincristine-induced apoptosis of leukaemia cells. [Abstract]

2020 Feb;24(4):2552-2565. PMID: 31930676

GLX351322 purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2020 Feb;24(4):2552-2565. [Abstract]

GLX351322 on the level of phospho-p38 MAPK in VCR-treated cells (*P < .05, NAC/VCR-treated cells compared to VCR-treated cells; GLX351322/VCR-treated cells compared to VCR-treated cells).
J Neurochem

Involvement of spinal NADPH oxidase 4 and endoplasmic reticulum stress in morphine-tolerant rats. [Abstract]

2024 Nov;168(11):3745-3759. PMID: 38069511
J Cell Physiol

NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells. [Abstract]

2021 Nov;236(11):7356-7375. PMID: 33982799
Mol Cell Endocrinol

Role of oncogene PIM-1 in the development and progression of papillary thyroid carcinoma: Involvement of oxidative stress. [Abstract]

2021 Mar 1:523:111144. PMID: 33383107
Mol Med Rep

NOX4 stimulates ANF secretion via activation of the Sirt1/Nrf2/ATF3/4 axis in hypoxic beating rat atria. [Abstract]

2022 Mar;25(3):84. PMID: 35029280
Toxicol Appl Pharmacol

Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway. [Abstract]

2023 Sep 1:474:116625. PMID: 37451322
Toxicol Appl Pharmacol

CREB/Sp1-mediated MCL1 expression and NFκB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells. [Abstract]

2022 Jan 15:435:115847. PMID: 34963561
J Cancer

Matrix stiffness regulates NPC invasiveness by modulating a mechanoresponsive TRPV4-Nox4-IL-8 signaling axis. [Abstract]

2025 Jan 13;16(4):1324-1334. PMID: 39895789
Cell Transplant

Dexamethasone Induces Senescence-Associated Changes in Trabecular Meshwork Cells by Increasing ROS Levels Via the TGFβ/Smad3-NOX4 Axis. [Abstract]

2023 Jan-Dec:32:9636897231177356. PMID: 37265069
Cell Transplant

Elevated Angiotensin-II Levels Contribute to the Pathogenesis of Open-Angle Glaucoma Via Inducing the Expression of Fibrosis-Related Genes in Trabecular Meshwork Cells Through a ROS/NOX4/SMAD3 Axis. [Abstract]

2023 Jan-Dec:32:9636897231162526. PMID: 36999649
Peptides

Cholecystokinin regulates atrial natriuretic peptide secretion through activation of NOX4-Sirt1-LEF1 signaling in beating rat hypoxic atria. [Abstract]

2024 Nov:181:171299. PMID: 39326462
Free Radic Res

Hypoxia induces proliferation via NOX4-Mediated oxidative stress and TGF-β3 signaling in uterine leiomyoma cells. [Abstract]

2022 Feb;56(2):163-172. PMID: 35377824
Exp Eye Res

NOX4 mediates ferroptosis through oxidative stress in diabetic keratopathy. [Abstract]

2026 Jul:268:111008. PMID: 41951167
J Integr Neurosci

Lentivirus-Mediated Missense Mutation in HtrA1 Leads to Activation of the TGF-β/Smads Pathway and Increased Apoptosis of Mouse Brain Microvascular Endothelial Cells via the Oxidative Stress Pathway. [Abstract]

2024 Oct 31;23(11):201. PMID: 39613464
Korean J Physiol Pharmacol

NOX4/Src regulates ANP secretion through activating ERK1/2 and Akt/GATA4 signaling in beating rat hypoxic atria. [Abstract]

2021 Mar 1;25(2):159-166. PMID: 33602886
bioRxiv

Type-I IFNs induce GBPs and lysosomal defense in hepatocytes to control malaria. [Abstract]

2024 Oct 24:2024.10.22.619707. PMID: 39484443
Research Square Preprint

2023 May 9.
Research Square Preprint

2023 May 9.
Oxid Med Cell Longev

Cholecystokinin Octapeptide Promotes ANP Secretion through Activation of NOX4-PGC-1 α-PPAR α/PPAR γ Signaling in Isolated Beating Rat Atria. [Abstract]

2022 Jun 20;2022:5905374. PMID: 35770043
Research Square Preprint

2020 Jul.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 20 mg/mL (46.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3174 mL

11.5872 mL

23.1744 mL

5 mM

0.4635 mL

2.3174 mL

4.6349 mL

10 mM

0.2317 mL

1.1587 mL

2.3174 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (2.32 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (2.32 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1 mg/mL (2.32 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 25 mg/mL (57.94 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Anvari E, et al. The novel NADPH oxidase 4 inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice. Free Radic Res. 2015;49(11):1308-18. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3174 mL	11.5872 mL	23.1744 mL	57.9361 mL
	5 mM	0.4635 mL	2.3174 mL	4.6349 mL	11.5872 mL
	10 mM	0.2317 mL	1.1587 mL	2.3174 mL	5.7936 mL
	15 mM	0.1545 mL	0.7725 mL	1.5450 mL	3.8624 mL
	20 mM	0.1159 mL	0.5794 mL	1.1587 mL	2.8968 mL
	25 mM	0.0927 mL	0.4635 mL	0.9270 mL	2.3174 mL
	30 mM	0.0772 mL	0.3862 mL	0.7725 mL	1.9312 mL
	40 mM	0.0579 mL	0.2897 mL	0.5794 mL	1.4484 mL

Keywords

GLX351322

55 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

GLX351322

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Glutamine Metabolism Compound Library

Anti-Cancer Metabolism Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) GLX351322

Alle NADPH Oxidase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (55)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GLX351322

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Glutamine Metabolism Compound Library

Anti-Cancer Metabolism Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) GLX351322

Alle NADPH Oxidase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (55)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GLX351322 Related Classifications

HY-100111 Related Classifications